Osmotica going down to Georgia with R&D/manufacturing operations; Aciex Therapeutics secures $8M;

@FierceBiotech: VC groups proffer $14.4M to back Yaupon's lymphoma drug app. Item | Follow @FierceBiotech

@JohnCFierce: This is pretty cool. Blurring electronics and biology, Air Force and NSF create light "smart skin." Piece | Follow @JohnCFierce

@RyanMFierce: Osmotica Pharma is heading down to Georgia, putting R&D/manufacturing facility in Marietta Story | Follow @RyanMFierce

@MaureenFierce: Dendreon's a Broken IPO, Again. News | Follow @MaureenFierce

> Aciex Therapeutics, a Westborough, MA-based developer of drugs for eye diseases, has brought in $8 million in equity financing. News

> Osmotica Pharmaceutical plans to open an R&D and manufacturing facility in Marietta, GA, bring 156 jobs to the site over a 5-year period. Report

> Norwegian firm Pronova BioPharma says that it's asked U.K. regulators for permission to advance its lead omega-3 fatty acid derivative, PRC-4016, in a Phase I clinical trial. Item

And Finally... A broader mandate for meningitis vaccination in Texas is ruffling some conservative feathers. Report

Pharma News

@FiercePharma: 90% of surveyed MDs know about Incivek and Victrelis. Majority prescribe both. Report #sermosurveys | Follow @FiercePharma

> Turkish private equity fund eyes stake in Bilim Ilac. News

> AZ to pay $2.5M in Idaho Medicaid case. Article

> Reuters: J&J chief gets president's ear on job growth. Report

> Pfizer reports "potentially improper payments" to feds. Story

> Time for Merck workers to sign for early retirement--or not. More

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.